(Q35107691)

6 August 2017

1 reference

title

Cytomegalovirus infection in solid organ transplantation: economic implications (English)

1 reference

6 August 2017

0 references

organ transplantation

1 reference

inferred from title

cytomegaloviral disease

1 reference

Ananya Das

1

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

21

1 reference

6 August 2017

issue

7

1 reference

6 August 2017

page(s)

467-475

1 reference

The economic impact of cytomegalovirus infection after liver transplantation

6 August 2017

cites work

1 reference

12 December 2020

Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Meta-analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients

1 reference

12 December 2020

Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease

1 reference

12 December 2020

A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients

1 reference

12 December 2020

Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients

1 reference

12 December 2020

The clinical utility of viral quantitation using molecular methods.

1 reference

12 December 2020

Incidence of cytomegalovirus infection and its relationship to donor-recipient serologic status in liver transplantation

1 reference

12 December 2020

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

1 reference

12 December 2020

New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients

1 reference

12 December 2020

Immunotherapy of CMV infections.

1 reference

12 December 2020

Cytomegalovirus prophylaxis in solid organ transplant recipients

1 reference

12 December 2020

Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database

1 reference

12 December 2020

Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: evidence for a beneficial effect of hyperimmune globulin.

1 reference

12 December 2020

The role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for the development of disease and should PCR be used to guide antiviral therapy?

1 reference

12 December 2020

A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation

1 reference

12 December 2020

Cytomegalovirus infection and prophylaxis in renal transplantation: financial considerations

1 reference

12 December 2020

Quantitation of cytomegalovirus: methodologic aspects and clinical applications.

1 reference

12 December 2020

Cytomegalovirus immune globulin after liver transplantation: a cost-effectiveness analysis 1

1 reference

12 December 2020

A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation

1 reference

12 December 2020

Summary of the International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis and Cytomegalovirus Infection.

1 reference

12 December 2020

A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients

1 reference

12 December 2020

PREEMPTIVE TREATMENT FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE

1 reference

12 December 2020

Long-term prognosis of renal transplantation after preemptive treatment of cytomegalovirus infection

1 reference

12 December 2020

Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment

1 reference

12 December 2020

Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice.

1 reference

12 December 2020

Association of cytomegalovirus genotype with graft rejection after liver transplantation

1 reference

12 December 2020

Impact of cytomegalovirus infection on organ transplant recipients

1 reference

12 December 2020

Clinical patterns and treatment of cytomegalovirus infection after solid-organ transplantation.

1 reference

12 December 2020

Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients

1 reference

12 December 2020

Hyperimmuneglobulin for cytomegalovirus prophylaxis following heart transplantation

1 reference

12 December 2020

Monitoring for cytomegalovirus infection in organ transplant recipients: analysis of pp65 antigen, DNA and late mRNA in peripheral blood leukocytes

1 reference

12 December 2020

High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial

1 reference

12 December 2020

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

1 reference

12 December 2020

Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy

1 reference

12 December 2020

A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation

1 reference

12 December 2020

Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipients

1 reference

12 December 2020

Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group

1 reference

12 December 2020

Cytomegalovirus infection and disease after liver transplantation

1 reference

12 December 2020

Costs and Outcomes of Prolonged Cytomegalovirus Prophylaxis to Cover the Enhanced Immunosuppression Phase Following Lung Transplantation

1 reference

12 December 2020

The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.

1 reference

12 December 2020

Cytomegalovirus infection--an etiological factor for rejection? A prospective study in 242 renal transplant patients

1 reference

12 December 2020

The laboratory diagnosis of cytomegalovirus infections

1 reference

12 December 2020

Cytomegalovirus disease and allograft loss after organ transplantation

1 reference

12 December 2020

The cost impact of cytomegalovirus disease in renal transplant recipients.

1 reference

12 December 2020

CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study

1 reference

12 December 2020

Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group

1 reference

12 December 2020

Virologic and pathogenetic aspects of cytomegalovirus infection.

1 reference

12 December 2020

Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis

1 reference

12 December 2020

Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?

1 reference

12 December 2020

Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients

1 reference

12 December 2020

Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients

1 reference

12 December 2020

Antigenemia in the Diagnosis and Monitoring of Active Cytomegalovirus Infection after Liver Transplantation

1 reference

12 December 2020

Cytomegalovirus infection, fulminant hepatitis, and liver transplantation: the sides of the triangle

1 reference

12 December 2020

Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis.

1 reference

12 December 2020

Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation

1 reference

12 December 2020

Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation.

1 reference

12 December 2020

Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients

1 reference

12 December 2020

Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients

1 reference

12 December 2020

Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis

1 reference

12 December 2020

Cytomegalovirus infection in organ transplant recipients.

1 reference

12 December 2020

Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation

1 reference

12 December 2020

Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies

1 reference

12 December 2020

A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts

1 reference

12 December 2020

Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants

1 reference

12 December 2020

Cytomegalovirus Disease as a Risk Factor for Graft Loss and Death After Orthotopic Liver Transplantation

1 reference

12 December 2020

Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation

1 reference

12 December 2020

Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial

1 reference

12 December 2020

Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients

1 reference

12 December 2020

Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation

1 reference

12 December 2020

Infections in solid-organ transplant recipients

1 reference

12 December 2020

A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients

1 reference

12 December 2020

10.2165/00019053-200321070-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

6 August 2017

1008090922

0 references

1 reference